A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma

Inclusion Criteria

• •Preoperative Criteria
• •Renal local advanced renal cell carcinoma and be suitable to radical nephrectomy.
• •Tumor \>=7cm, the lymph nodes in metastasis can be resectable, the renal vein or inferior caval vein with metastatic thrombus can be resectable also, clinical staging\>=T2anyNMo.
• •Resectable tumor with multiple-lesion in ipsolateral kidney Enrolment Criteria
• •No distant metastasis.
• •Not undergoing any adjuvant or systematic anti-tumor therapy, such as chemotherapy, biotherapy or radiotherapy.
• •After the nephrectomy 4-12 weeks and should be recovery in the postoperative complications.
• •ECOG scores 0-1.
• •Referring to the Scoring Algorithm to Predict Metastasis after Radical Nephrectomy in Patients with clear cell renal cell carcinoma, all the patients score higher than 6. Metastatic lymph node with clinical diagnosis have been resected, all the resected specimen edge be negative in pathological detection.
• •The pathological diagnosis of renal cell carcinoma:
• •No remnant tumor with postoperative imaging screening with CT or MRI.
• •The liver and renal function, hemocytogenesis function meet the below criteria within the 4 weeks before the enrollment.
• •* Granulocytes count \>1500/mm3
• •* Blood platelet \>100000/mm3
• •* Creatinine\<2 times of the upper of the reference value
• •* Total bilirubin\<1.5 times of the upper of the reference value
• •* Alanine aminotransferase/aspartate aminotransferase\<2.5 times of the upper of the reference value
• •* The informed consent has been endorsed.